On August 6, 2026 Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare platform, reported the first participant has been dosed in a Phase 1 clinical trial evaluating the safety and efficacy of DISP-10 in adult participants with advanced gastrointestinal (GI) cancers, including colorectal cancer, gastric adenocarcinoma, esophageal adenocarcinoma, and gastroesophageal adenocarcinoma. The participant was treated with both DV-10 and ide-cel components of DISP-10 and completed the protocol-defined dose-limiting toxicity (DLT) evaluation period. Additionally, DISP-10 has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of advanced GI cancers. DISP-10 is a novel, investigational therapy designed to address key challenges in the treatment of solid tumors.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Initiating this trial represents a meaningful step forward for patients with advanced GI cancers, reinforced by the FDA’s Fast Track designation for DISP-10," said Mauro Avanzi, M.D., Ph.D., Chief Medical Officer of Dispatch. "We look forward to advancing this study as we work to overcome the longstanding limitations of treating solid tumors with immunotherapy, including lack of a safe and homogeneously expressed target antigen, a narrow therapeutic window, and an inhibitory tumor microenvironment. DISP-10 aims to address these barriers with our novel approach."
DISP-10 consists of two components. The first component, DV-10, is a tumor-specific virus engineered to deliver a modified B cell maturation antigen (dBCMA), along with IL-18 and CXCL9, to "paint" a synthetic antigen onto tumor cells, remodel the tumor microenvironment to support T cell function, and help enhance T cell trafficking into tumors. The second component is ide-cel, Bristol Myers Squibb’s BCMA-directed CAR T cell therapy approved in the U.S.* By leveraging components with significant clinical experience, Dispatch aims to proceed rapidly through clinical development and ultimately bring a major advancement and option to patients suffering from advanced GI cancers, including colorectal cancer, which currently is the leading cause of cancer death among people under age 50.1
"Patients with advanced GI cancers can face a challenging prognosis, often measured in a handful of months with limited treatment options beyond chemotherapy," said Marwan Fakih, M.D., Division Chief, GI Medical Oncology and Deputy Director, City of Hope Comprehensive Cancer Center. "There is a clear need for new approaches, and the initiation of this study with DISP-10 is an important step toward exploring a novel strategy that may expand the reach of immunotherapy treatments for patients."
The first-in-human, Phase 1, multicenter, open-label clinical study is designed to evaluate the safety, tolerability, and activity of DISP-10. The FDA’s Fast Track designation is intended to accelerate the development and review of investigational therapies that have demonstrated their potential to address serious conditions with unmet medical need. The designation enables more frequent engagement with the FDA and may allow for rolling review and other mechanisms to expedite the regulatory process.
*Ide-cel has not been studied and is not approved for use in solid tumors.
(Press release, Dispatch Bio, AUG 6, 2026, View Source [SID1234669836])